4574 — Taiko Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥17bn
- ¥15bn
- ¥6bn
- 37
- 11
- 60
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.58 | ||
| Price to Tang. Book | 2.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.41% | ||
| Return on Equity | -48.85% | ||
| Operating Margin | -63.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 10,418.65 | 14,966.17 | 11,299 | 5,040 | 6,120 | n/a | n/a | -8.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +20.45 | +89.89 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
Directors
- Hitoshi Shibata CHM (67)
- Takashi Shibata PRE (57)
- Tomosada Yoshikawa SMD (53)
- Atsunori Kato EDR (57)
- Masami Moroi EDR (62)
- Masashi Terakami EDR (60)
- Takaaki Higashino OTH (48)
- Hideo Inagaki DRC (62)
- Motoo Matsuzawa DRC
- Kazuo Nakazawa IND
- Koki Yanagisawa IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 18th, 1946
- Public Since
- March 18th, 2009
- No. of Shareholders
- 16,452
- No. of Employees
- 208
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 50,149,777
- Address
- 16F, ORIX Hommachi Bldg, OSAKA-SHI, 550-0005
- Web
- https://www.seirogan.co.jp/
- Phone
- +81 643911110
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4574
Similar to 4574
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Taiko Pharmaceutical Co share price?
As of Today at 19:21 UTC, shares in Taiko Pharmaceutical Co are trading at ¥347. This share price information is delayed by 15 minutes.
How has the Taiko Pharmaceutical Co share price performed this year?
Shares in Taiko Pharmaceutical Co last closed at ¥347 and the price had moved by -7.71% over the past 365 days. In terms of relative price strength the Taiko Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -30.2% over the past year.
What are the analyst and broker recommendations for Taiko Pharmaceutical Co?
The overall consensus recommendation for Taiko Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Taiko Pharmaceutical Co dividend yield?
Taiko Pharmaceutical Co does not currently pay a dividend.
Does Taiko Pharmaceutical Co pay a dividend?
Taiko Pharmaceutical Co does not currently pay a dividend.
When does Taiko Pharmaceutical Co next pay dividends?
Taiko Pharmaceutical Co does not currently pay a dividend.
How do I buy Taiko Pharmaceutical Co shares?
To buy shares in Taiko Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Taiko Pharmaceutical Co?
As of the previous close price of ¥347, shares in Taiko Pharmaceutical Co had a market capitalisation of ¥17bn.
Where are Taiko Pharmaceutical Co shares listed?
Here are the trading details for Taiko Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4574
What kind of share is Taiko Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Taiko Pharmaceutical Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Taiko Pharmaceutical Co share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Taiko Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Taiko Pharmaceutical Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -14.22%.
As of the last closing price of ¥347, shares in Taiko Pharmaceutical Co were trading +4.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Taiko Pharmaceutical Co PE Ratio?
The Taiko Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥347.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Taiko Pharmaceutical Co?
Taiko Pharmaceutical Co's management team is headed by:
- Hitoshi Shibata - CHM
- Takashi Shibata - PRE
- Tomosada Yoshikawa - SMD
- Atsunori Kato - EDR
- Masami Moroi - EDR
- Masashi Terakami - EDR
- Takaaki Higashino - OTH
- Hideo Inagaki - DRC
- Motoo Matsuzawa - DRC
- Kazuo Nakazawa - IND
- Koki Yanagisawa - IND